DK0921812T4 - Insulinpræparater, som indeholder et halogenid - Google Patents

Insulinpræparater, som indeholder et halogenid

Info

Publication number: DK0921812T4
Authority: DK; Denmark
Prior art keywords: halide; insulin preparations; preparations containing; insulin; halogenide
Prior art date: 1996-06-20

Application number

DK97928123.5T

Other languages

English (en)

Other versions

DK0921812T3 (da

Inventor

Elsebeth Norup

Liselotte Langkjaer

Svend Havelund

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-20

Filing date

1997-06-19

Publication date

2012-04-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8096378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0921812(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-06-19 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2002-02-11 Publication of DK0921812T3 publication Critical patent/DK0921812T3/da

2012-04-02 Application granted granted Critical

2012-04-02 Publication of DK0921812T4 publication Critical patent/DK0921812T4/da

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 4
102000004877 Insulin Human genes 0.000 title abstract 2
108090001061 Insulin Proteins 0.000 title abstract 2
229940125396 insulin Drugs 0.000 title abstract 2
238000002360 preparation method Methods 0.000 title abstract 2
150000004820 halides Chemical class 0.000 title 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
229930195725 Mannitol Natural products 0.000 abstract 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
239000000594 mannitol Substances 0.000 abstract 1
235000010355 mannitol Nutrition 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Inorganic Chemistry (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK97928123.5T 1996-06-20 1997-06-19 Insulinpræparater, som indeholder et halogenid DK0921812T4 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK68596		1996-06-20
PCT/DK1997/000268 WO1997048414A1 (en)	1996-06-20	1997-06-19	INSULIN PREPARATIONS CONTAINING NaCl

Publications (2)

Publication Number	Publication Date
DK0921812T3 DK0921812T3 (da)	2002-02-11
DK0921812T4 true DK0921812T4 (da)	2012-04-02

Family

ID=8096378

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK97928123.5T DK0921812T4 (da)	1996-06-20	1997-06-19	Insulinpræparater, som indeholder et halogenid

Country Status (21)

Country	Link
EP (1)	EP0921812B2 (da)
JP (2)	JP4404380B2 (da)
KR (1)	KR100451778B1 (da)
CN (1)	CN1120019C (da)
AT (1)	ATE208208T1 (da)
AU (1)	AU720484B2 (da)
BR (1)	BR9709845B1 (da)
CA (1)	CA2258097C (da)
CZ (1)	CZ297937B6 (da)
DE (1)	DE69708121T3 (da)
DK (1)	DK0921812T4 (da)
ES (1)	ES2167751T5 (da)
HU (1)	HU228094B1 (da)
IL (2)	IL127366A0 (da)
NO (1)	NO324430B1 (da)
PL (1)	PL189964B1 (da)
PT (1)	PT921812E (da)
RU (1)	RU2182015C2 (da)
UA (1)	UA49890C2 (da)
WO (1)	WO1997048414A1 (da)
ZA (1)	ZA975470B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69924232D1 (de) *	1998-01-09	2005-04-21	Novo Nordisk As	Stabilisierte insulin-zubereitungen
WO2000029013A1 (en) *	1998-11-18	2000-05-25	Novo Nordisk A/S	Stable aqueous insulin preparations without phenol and cresol
US6489292B1 (en)	1998-11-18	2002-12-03	Novo Nordisk A/S	Stable aqueous insulin preparations without phenol and cresol
JP2002535287A (ja) *	1999-01-26	2002-10-22	イーライ・リリー・アンド・カンパニー	単分散性６量体のアシル化されたインスリンアナログ製剤
WO2000059499A1 (en) *	1999-04-05	2000-10-12	Verteletsky, Pavel Vasilievich	Use of succinic acid or salts thereof for the treatment of diabetes mellitus and wound healing
EP1523993A1 (en) *	1999-12-16	2005-04-20	Eli Lilly & Company	Polypeptide compositions with improved stability
WO2001043762A2 (en) *	1999-12-16	2001-06-21	Eli Lilly And Company	Polypeptide compositions with improved stability
US7022674B2 (en)	1999-12-16	2006-04-04	Eli Lilly And Company	Polypeptide compositions with improved stability
SI2918286T1 (sl)	2004-10-05	2020-06-30	Novo Nordisk A/S	Farmacevtski pripravek, ki vsebuje inzulin v kristalni obliki in tudi v obliki raztopine
RU2288000C1 (ru) *	2005-04-27	2006-11-27	Институт нефтехимического синтеза им. А.В. Топчиева РАН (ИНХС РАН)	Раствор инсулина для перорального введения
PT3228320T (pt)	2008-10-17	2020-03-26	Sanofi Aventis Deutschland	Combinação de uma insulina e de um agonista do glp-1
JP5832439B2 (ja)	2009-11-13	2015-12-16	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
SG10201500871TA (en)	2009-11-13	2015-04-29	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist and methionine
CN103179978A (zh)	2010-08-30	2013-06-26	赛诺菲-安万特德国有限公司	Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja)	2011-08-29	2018-08-01	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
MX2015006997A (es)	2012-12-26	2015-09-23	Wockhardt Ltd	Composicion farmaceutica.
TWI780236B (zh)	2013-02-04	2022-10-11	法商賽諾菲公司	胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
JP6641280B2 (ja)	2014-01-09	2020-02-05	サノフイＳａｎｏｆｉ	インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
KR20160104726A (ko)	2014-01-09	2016-09-05	사노피	인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형
JP2020114861A (ja) *	2014-01-09	2020-07-30	サノフイＳａｎｏｆｉ	インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
JP2020143105A (ja) *	2014-01-09	2020-09-10	サノフイＳａｎｏｆｉ	インスリンアスパルトの安定化された医薬製剤
CA2932873A1 (en) *	2014-01-09	2015-07-16	Sanofi	Stabilized pharmaceutical formulations of insulin aspart
CN107206058A (zh)	2014-12-12	2017-09-26	赛诺菲-安万特德国有限公司	甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
SG11202111312UA (en)	2019-06-14	2021-12-30	Zealand Pharma As	Pharmaceutical parenteral composition of dual glp1/2 agonist
EP4243770A1 (en) *	2020-11-16	2023-09-20	W. L. Gore & Associates, Inc.	Formulations, methods, and pre-filled multi-dose injection devices without cloud point

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK116527B (da) *	1967-03-01	1970-01-19	Nordisk Insulinlab	Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse.
SU1528496A1 (ru) *	1972-10-17	1989-12-15	Днепропетровский Научно-Исследовательский Институт Гастроэнтерологии	Дегидратирующее средство
US4783441A (en) †	1979-04-30	1988-11-08	Hoechst Aktiengesellschaft	Aqueous protein solutions stable to denaturation
US4439181A (en) *	1981-01-26	1984-03-27	Regents Of The University Of Minnesota	Polyol-hormone mixture for use in chronic parenteral hormone administration
AU550068B2 (en) †	1981-03-10	1986-02-27	Novo Nordisk A/S	Zinc insulin stabilized with calcium or magnesium salts
US4839341A (en) *	1984-05-29	1989-06-13	Eli Lilly And Company	Stabilized insulin formulations
PH25772A (en) *	1985-08-30	1991-10-18	Novo Industri As	Insulin analogues, process for their preparation
IL93282A (en) *	1989-02-09	1995-08-31	Lilly Co Eli	Insulin analogues
EP0705275B1 (en) *	1993-06-21	1999-02-03	Novo Nordisk A/S	Asp-b28 insulin crystals
NZ273285A (en) *	1993-09-17	1997-10-24	Novo Nordisk As	Insulin derivatives and compositions thereof
US5461031A (en) *	1994-06-16	1995-10-24	Eli Lilly And Company	Monomeric insulin analog formulations
US5474978A (en) *	1994-06-16	1995-12-12	Eli Lilly And Company	Insulin analog formulations

1997
- 1997-06-19 HU HU9904031A patent/HU228094B1/hu unknown
- 1997-06-19 IL IL12736697A patent/IL127366A0/xx active IP Right Grant
- 1997-06-19 DE DE69708121T patent/DE69708121T3/de not_active Expired - Lifetime
- 1997-06-19 AT AT97928123T patent/ATE208208T1/de active
- 1997-06-19 CA CA2258097A patent/CA2258097C/en not_active Expired - Lifetime
- 1997-06-19 CZ CZ0395698A patent/CZ297937B6/cs not_active IP Right Cessation
- 1997-06-19 ES ES97928123T patent/ES2167751T5/es not_active Expired - Lifetime
- 1997-06-19 JP JP50212998A patent/JP4404380B2/ja not_active Expired - Lifetime
- 1997-06-19 PL PL97330763A patent/PL189964B1/pl unknown
- 1997-06-19 EP EP97928123A patent/EP0921812B2/en not_active Expired - Lifetime
- 1997-06-19 RU RU99101068/14A patent/RU2182015C2/ru active
- 1997-06-19 KR KR10-1998-0710429A patent/KR100451778B1/ko not_active Expired - Lifetime
- 1997-06-19 CN CN97195648A patent/CN1120019C/zh not_active Expired - Lifetime
- 1997-06-19 PT PT97928123T patent/PT921812E/pt unknown
- 1997-06-19 WO PCT/DK1997/000268 patent/WO1997048414A1/en not_active Ceased
- 1997-06-19 BR BRPI9709845-0A patent/BR9709845B1/pt not_active IP Right Cessation
- 1997-06-19 UA UA98126686A patent/UA49890C2/uk unknown
- 1997-06-19 DK DK97928123.5T patent/DK0921812T4/da active
- 1997-06-19 AU AU32536/97A patent/AU720484B2/en not_active Expired
- 1997-06-20 ZA ZA9705470A patent/ZA975470B/xx unknown
1998
- 1998-12-02 IL IL127366A patent/IL127366A/en not_active IP Right Cessation
- 1998-12-18 NO NO19985981A patent/NO324430B1/no not_active IP Right Cessation
2009
- 2009-05-07 JP JP2009112970A patent/JP2009235075A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
RU2182015C2 (ru)	2002-05-10
KR20000022031A (ko)	2000-04-25
AU720484B2 (en)	2000-06-01
DE69708121T3 (de)	2012-05-16
UA49890C2 (uk)	2002-10-15
DK0921812T3 (da)	2002-02-11
PT921812E (pt)	2002-04-29
BR9709845A (pt)	1999-08-10
KR100451778B1 (ko)	2004-11-16
EP0921812B2 (en)	2011-12-21
ES2167751T5 (es)	2012-03-30
DE69708121T2 (de)	2002-08-01
ZA975470B (en)	1997-12-22
CN1120019C (zh)	2003-09-03
PL189964B1 (pl)	2005-10-31
DE69708121D1 (de)	2001-12-13
CZ297937B6 (cs)	2007-05-02
EP0921812B1 (en)	2001-11-07
ES2167751T3 (es)	2002-05-16
ATE208208T1 (de)	2001-11-15
NO324430B1 (no)	2007-10-15
HU228094B1 (en)	2012-10-29
NO985981D0 (no)	1998-12-18
CA2258097A1 (en)	1997-12-24
JP2009235075A (ja)	2009-10-15
PL330763A1 (en)	1999-05-24
EP0921812A1 (en)	1999-06-16
JP4404380B2 (ja)	2010-01-27
IL127366A (en)	2007-07-04
WO1997048414A1 (en)	1997-12-24
BR9709845B1 (pt)	2008-11-18
JP2000513344A (ja)	2000-10-10
NO985981L (no)	1998-12-18
AU3253697A (en)	1998-01-07
HUP9904031A3 (en)	2000-10-30
CZ395698A3 (cs)	1999-05-12
IL127366A0 (en)	1999-10-28
CA2258097C (en)	2011-02-08
CN1222083A (zh)	1999-07-07
HUP9904031A2 (hu)	2000-04-28

Publication	Publication Date	Title
NO985981L (no)	1998-12-18	Insulinpreparater som inneholder NaCl
DK0428038T3 (da)	1994-08-29	Transdermal administration af 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
FI881660A7 (fi)	1989-10-12	Foerfarande och anordning foer separering av gas med pumpen ur mediet som skall pumpas.
NO952357L (no)	1995-12-18	Formulering av insulinanaloger
FI872967A7 (fi)	1989-01-07	Pump och foerfarande foer separering av gas med pumpen ur mediet som skall pumpas.
YU59092A (sh)	1994-12-28	Formulacije aerosola koji ne sadrže hlorofluorougljenična jedinjenja
DE68924540D1 (de)	1995-11-16	Medizinische Aerosolformulierungen.
DK1172114T3 (da)	2005-01-24	Stabile koncentrerede insulinpræparater til pulmonær indgivelse
NO893769D0 (no)	1989-09-22	Fremgangsmaate for behandling av naturgass.
DZ1835A1 (fr)	2002-02-17	Nouvelles formulations.
DK254787D0 (da)	1987-05-19	Farmaceutiske praeparater til behandling af sygdomme foraarsaget af oxidativt stress og indeholdende 2-phenyl.1,2-benziso-selenazol-3(2h)-on som aktiv bestanddel
DE3586959D1 (de)	1993-02-18	Desinfektionsverfahren sowie zusammensetzung dafuer.
NO995831D0 (no)	1999-11-26	Injiserbar, klar formulering av et anestetisk middel
ATE38036T1 (de)	1988-11-15	Benzothiophenderivate als bronchodilatoren.
NO870212L (no)	1987-07-20	Fremgangsmaate for fremstilling av stabile nikorandilpreparater.
ATE11547T1 (de)	1985-02-15	Neue d-homosteroide, ihre verwendung und herstellung, sowie pharmazeutische praeparate damit.
NO893062L (no)	1990-01-30	Anvendelse av isokinolinforbindelser, saerlig i inhalasjonspreparater.
ATE92542T1 (de)	1993-08-15	Azeotropaehnliche zusammensetzungen von 1,1dichlor-2,2,2-trifluoraethan und 1,1-dochlor-1fluor\|than.
ATE283706T1 (de)	2004-12-15	ßGEGEN RACEMISIERUNG STABILISIERTE PHARMAZEUTISCHE ZUBEREITUNGEN VON CILANSETRONß
ES2152315T3 (es)	2001-02-01	Xamoneline tartrato.
ATE196914T1 (de)	2000-10-15	Lh-rh analoge mit starrer konformation, deren verwendungen und pharmazeutische zusammensetzungen
EP0270841A3 (de)	1988-07-20	2-Methyl-3-(p-methyl-phenyl)-propionitril, dessen Herstellung und Verwendung als Riechstoff
DK0626173T3 (da)	1997-05-12	Aerosolpræparat indeholdende fusafungin
ATE204286T1 (de)	2001-09-15	Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge
ATE80143T1 (de)	1992-09-15	Isomere formyl-trimethylbicyclo(2,2,2)oct-7-ene.